Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 70% Improvement Relative Risk Mortality (b) 67% early Mortality (c) 77% Mortality (d) 84% Mortality (e) -29% HCQ for COVID-19  Corradini et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 1,713 patients in Italy Lower mortality with HCQ (p<0.000001) Corradini et al., Internal and Emergen.., Apr 2021 Favors HCQ Favors control

Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI)

Corradini et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02742-8
Apr 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 3,044 hospitalized COVID-19 patients in Italy, showing HCQ significantly associated with survival in light, mild, and moderate cases in multivariable analysis, but not in severe cases.
risk of death, 70.2% lower, OR 0.30, p < 0.001, treatment 1,439, control 274, adjusted per study, Table S6, all patients, multivariable, RR approximated with OR.
risk of death, 67.4% lower, OR 0.33, p = 0.01, treatment 641, control 102, adjusted per study, Table S6, light condition patients, multivariable, RR approximated with OR, early treatment result.
risk of death, 76.8% lower, OR 0.23, p < 0.001, treatment 546, control 71, adjusted per study, Table S6, mild condition patients, multivariable, RR approximated with OR.
risk of death, 84.2% lower, OR 0.16, p < 0.001, treatment 184, control 64, adjusted per study, Table S6, moderate condition patients, multivariable, RR approximated with OR.
risk of death, 29.0% higher, OR 1.29, p = 0.73, treatment 68, control 37, adjusted per study, Table S6, severe condition patients, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Corradini et al., 24 Apr 2021, retrospective, Italy, peer-reviewed, 60 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI)
Elena Corradini, Paolo Ventura, Walter Ageno, Chiara Beatrice Cogliati, Maria Lorenza Muiesan, Domenico Girelli, Mario Pirisi, Antonio Gasbarrini, Paolo Angeli, Patrizia Rovere Querini, Emanuele Bosi, Moreno Tresoldi, Roberto Vettor, Marco Cattaneo, Fabio Piscaglia, Antonio Luca Brucato, Stefano Perlini, Paolo Martelletti, Roberto Pontremoli, Massimo Porta, Pietro Minuz, Oliviero Olivieri, Giorgio Sesti, Gianni Biolo, Damiano Rizzoni, Gaetano Serviddio, Francesco Cipollone, Davide Grassi, Roberto Manfredini, Guido Luigi Moreo, Antonello Pietrangelo, Elisabetta Tombolini, Thomas Teatini, Pier Ernesto Crisafulli, Pier Paolo Sainaghi, Lorenzo Zileri Dal Verme, Salvatore Piano, Rebecca De Lorenzo, Gaetano Arcidiacono, Marco Podda, Luca Muratori, Claudia Gabiati, Francesco Salinaro, Michelangelo Luciani, Cecilia Barnini, Stefania Morra Di Cella, Andrea Dalbeni, Simonetta Friso, Michelangelo Luciani, Filippo Mearelli, Paolo Malerba, Francesco Cavallone, Damiano D’ardes, Serena Notargiacomo, Alfredo De Giorgi, Marta Mansi, Elena Buzzetti, Andrea Ricci, Francesca Martelli
Internal and Emergency Medicine, doi:10.1007/s11739-021-02742-8
During the COVID-19 2020 outbreak, a large body of data has been provided on general management and outcomes of hospitalized COVID-19 patients. Yet, relatively little is known on characteristics and outcome of patients managed in Internal Medicine Units (IMU). To address this gap, the Italian Society of Internal Medicine has conducted a nationwide cohort multicentre study on death outcome in adult COVID-19 patients admitted and managed in IMU. This study assessed 3044 COVID-19 patients at 41 referral hospitals across Italy from February 3rd to May 8th 2020. Demographics, comorbidities, organ dysfunction, treatment, and outcomes including death were assessed. During the study period, 697 patients (22.9%) were transferred to intensive care units, and 351 died in IMU (death rate 14.9%). At admission, factors independently associated with in-hospital mortality were age (OR 2.46, p = 0.000), productive cough (OR 2.04, p = 0.000), pre-existing chronic heart failure (OR 1.58, p = 0.017) and chronic obstructive pulmonary disease (OR 1.17, p = 0.048), the number of comorbidities (OR 1.34, p = 0.000) and polypharmacy (OR 1.20, p = 0.000). Of note, up to 40% of elderly patients did not report fever at admission. Decreasing PaO 2 /FiO 2 ratio at admission was strongly inversely associated with survival. The use of conventional oxygen supplementation increased with the number of pre-existing comorbidities, but it did not associate with better survival in patients with PaO 2 /FiO 2 ratio < 100. The latter, significantly benefited by the early use of non-invasive mechanical ventilation. Our study identified PaO 2 /FiO 2 ratio at admission and comorbidity as the main alert signs to inform clinical decisions and resource allocation in non-critically ill COVID-19 patients admitted to IMU.
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s11739-021-02742-8. Conflict of interest The authors have no conflicts of interest to declare that are relevant to the content of this article. Ethics approval The participating centers had the approval from the local ethical committee. Authors and Affiliations Elena Corradini
Ageno, Cogliati, Perego, Clinical risk scores for the early prediction of severe outcomes in patients hospitalized for COVID-19, Intern Emerg Med, doi:10.1007/s11739-020-02617-4
Albani, Fusina, Granato, Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients, Sci Rep, doi:10.1038/s41598-020-80654-x
Bahat, Covid-19 and the renin angiotensin system: implications for the older adults, J Nutr Health Aging, doi:10.1007/s12603-020-1403-7
Behl, Kaur, Bungau, The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions, Life Sci, doi:10.1016/j.lfs.2020.118075
Bellani, Grasselli, Cecconi, Noninvasive ventilatory support of COVID-19 patients outside the intensive care units (WARd-COVID), Ann Am Thorac Soc, doi:10.1513/AnnalsATS.202008-1080OC
Domenico, Coen, Bergamaschi, Clinical characteristics and respiratory support of 310 COVID-19 patients, diagnosed at the emergency room: a single-center retrospective study, Intern Emerg Med, doi:10.1007/s11739-020-02548-0
Ferreyro, Angriman, Scales, Noninvasive oxygenation strategies for acute hypoxemic respiratory failure-reply, JAMA, doi:10.1001/jama.2020.18602
Garibaldi, Fiksel, Muschelli, Patient trajectories among persons hospitalized for COVID-19: a cohort study, Ann Intern Med, doi:10.7326/M20-3905
Grasselli, Tonetti, Protti, Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study, Lancet Respir Med, doi:10.1016/S2213-2600(20)30370-2
Grippo, Navarra, Orsi, The role of COVID-19 in the death of SARS-CoV-2-positive patients: a study based on death certificates, J Clin Med, doi:10.3390/jcm9113459
Group, Horby, Lim, Dexamethasone in hospitalized patients with Covid-19, N Engl J Med
Guaraldi, Meschiari, Cozzi-Lepri, Tocilizumab in patients with severe COVID-19: a retrospective cohort study, Lancet Rheumatol, doi:10.1016/S2665-9913(20)30173-9
Gupta, Hayek, Factors associated with death in critically ill patients with coronavirus disease 2019 in the US, JAMA Intern Med, doi:10.1001/jamainternmed.2020.3596
Lenti, Corazza, Sabatino, Carving out a place for internal medicine during COVID-19 epidemic in Italy, J Intern Med, doi:10.1111/joim.13079
Mancia, Rea, Ludergnani, Renin-angiotensinaldosterone system blockers and the risk of Covid-19, N Engl J Med, doi:10.1056/NEJMoa2006923
Montagnani, Pieralli, Gnerre, COVID-19 pandemic and internal medicine units in Italy: a precious effort on the front line, Intern Emerg Med, doi:10.1007/s11739-020-02454-5
Nunez-Gil, Fernandez-Perez, Estrada, Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry, Intern Emerg Med, doi:10.1007/s11739-020-02543-5
Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA, doi:10.1001/jama.2020.4683
Palmieri, Vanacore, Donfrancesco, Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy, J Gerontol A Biol Sci Med Sci, doi:10.1093/gerona/glaa146
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area, JAMA, doi:10.1001/jama.2020.6775
Salama, Han, Yau, Tocilizumab in patients hospitalized with Covid-19 pneumonia, N Engl J Med, doi:10.1056/NEJMoa2030340
Soria, Galimberti, Lapadula, The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19, PLoS ONE, doi:10.1371/journal.pone.0246170
Wiersinga, Rhodes, Cheng, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, JAMA, doi:10.1001/jama.2020.12839
Wongvibulsin, Garibaldi, Antar, Development of severe COVID-19 adaptive risk predictor (SCARP), a calculator to predict severe disease or death in hospitalized patients with COVID-19, Ann Intern Med, doi:10.7326/M20-6754
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop